Utility of heel ultrasound (HUS) fracture prediction output as a surrogate for a fracture prediction output from dual x-ray absorptiometry DEXA in perimenopausal, menopausal, or postmenopausal female subjects being evaluated for osteoporosis treatment.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.